None listed
Conditions
Interventions
Drug : 1. Ondansetron (Onseran, 8mg, 4ml, Yuhan, Group O) or normal saline (4ml, Group Ca) infusion via intravenous line
2. Ondansetron or normal saline 5-10 minutes before spinal anesthetic drug i
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Singleton, Gestational age 37 weeks or more 2) Scheduled for spinal anesthesia 3) from 20 years to 45 years 4) No contraindications of spinal anesthesia 5) Body mass index 35 kg/m2 or less 6) American society of anesthesiologists physical status 2
Exclusion criteria
Exclusion criteria: 1) Past history of side effects related to the use of ondansetron, history of inadequate response to the antiemetic effect of ondansetron 2) Failure of spinal anesthesia (conversion to general anesthesia, unexpected analgesia or sedatives administration due to inadequate spinal anesthesia) 3) Emergency cesarean section (category 1) such as placental abruption, umbilical cord prolapse 4) Cases where blood transfusion is expected (etc. placenta accreta spectrum) 5) Accompanying pregnancy related complications such as hypertension, pre-eclampsia, eclampsia , etc 6) Magnesium treatment during the pre/postoperative period 7) Electrolyte imbalance including hypokalemia, hypomagnesemia and others, Drug administration causing electrolyte imbalance 8) Congestive heart failure, possibility or presence of Long QT syndrome, and brady-arrhythmia 9) Administration of Selective-serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor 10) Drug administration related to QT prolongation: Cardiotoxic drugs (e.g.anthracycline), antibiotics (e.g.erythromycin), anti-fungal agents (e.g.ketoconazol), anti-arrhythmic agents (e.g.amiodarone), beta-blocker, etc 11) If there is or is expected to be a neurological deficit 12) Expected birth weight less than 1500 (Very low birth weight) 13) Patient who have already administered a Selective 5-HT3 receptor antagonist, or patients having an allergy or hypersensitivity to selective 5-HT3 receptor antagonist 14) Regarded as inappropriate to participate this study by Medical staff
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of vasopressor before baby delivery | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of corrected QT after administration of a drug | — |
Countries
Korea, Republic of
Contacts
Public ContactHeesun Park
Asan Medical Center
Outcome results
None listed